175 related articles for article (PubMed ID: 27274007)
1. Pharmacokinetic and Pharmacodynamic Drug Interaction Study of Piragliatin, a Glucokinase Activator, and Glyburide, a Sulfonylurea, in Type 2 Diabetic Patients.
Zhai S; Georgy A; Liang Z; Zhi J
Clin Pharmacol Drug Dev; 2016 Nov; 5(6):552-556. PubMed ID: 27274007
[TBL] [Abstract][Full Text] [Related]
2. Glycemic Effect and Safety of a Systemic, Partial Glucokinase Activator, PF-04937319, in Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin-A Randomized, Crossover, Active-Controlled Study.
Denney WS; Denham DS; Riggs MR; Amin NB
Clin Pharmacol Drug Dev; 2016 Nov; 5(6):517-527. PubMed ID: 27870481
[TBL] [Abstract][Full Text] [Related]
3. Lack of Potential Pharmacokinetic and Pharmacodynamic Interactions Between Piragliatin, a Glucokinase Activator, and Simvastatin in Patients With Type 2 Diabetes Mellitus.
Georgy A; Zhai S; Liang Z; Boldrin M; Zhi J
J Clin Pharmacol; 2016 Jun; 56(6):675-82. PubMed ID: 26381165
[TBL] [Abstract][Full Text] [Related]
4. Effects of piragliatin, a glucokinase activator, on fasting and postprandial plasma glucose in patients with type 2 diabetes mellitus.
Zhi J; Zhai S
J Clin Pharmacol; 2016 Feb; 56(2):231-8. PubMed ID: 26183686
[TBL] [Abstract][Full Text] [Related]
5. Piragliatin (RO4389620), a novel glucokinase activator, lowers plasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus: a mechanistic study.
Bonadonna RC; Heise T; Arbet-Engels C; Kapitza C; Avogaro A; Grimsby J; Zhi J; Grippo JF; Balena R
J Clin Endocrinol Metab; 2010 Nov; 95(11):5028-36. PubMed ID: 20739378
[TBL] [Abstract][Full Text] [Related]
6. Exploratory effects of a strong CYP3A inhibitor (ketoconazole), a strong CYP3A inducer (rifampicin), and concomitant ethanol on piragliatin pharmacokinetics and pharmacodynamics in type 2 diabetic patients.
Zhi J; Zhai S; Georgy A; Liang Z; Boldrin M
J Clin Pharmacol; 2016 May; 56(5):548-54. PubMed ID: 26272330
[TBL] [Abstract][Full Text] [Related]
7. Discovery of piragliatin--first glucokinase activator studied in type 2 diabetic patients.
Sarabu R; Bizzarro FT; Corbett WL; Dvorozniak MT; Geng W; Grippo JF; Haynes NE; Hutchings S; Garofalo L; Guertin KR; Hilliard DW; Kabat M; Kester RF; Ka W; Liang Z; Mahaney PE; Marcus L; Matschinsky FM; Moore D; Racha J; Radinov R; Ren Y; Qi L; Pignatello M; Spence CL; Steele T; Tengi J; Grimsby J
J Med Chem; 2012 Aug; 55(16):7021-36. PubMed ID: 22809456
[TBL] [Abstract][Full Text] [Related]
8. Comparison of extended-release metformin in combination with a sulfonylurea (glyburide) to sulfonylurea monotherapy in adult patients with type 2 diabetes: a multicenter, double-blind, randomized, controlled, phase III study.
Lewin A; Lipetz R; Wu J; Schwartz S
Clin Ther; 2007 May; 29(5):844-855. PubMed ID: 17697903
[TBL] [Abstract][Full Text] [Related]
9. Dose selection using a semi-mechanistic integrated glucose-insulin-glucagon model: designing phase 2 trials for a novel oral glucokinase activator.
Zhang X; Schneck K; Bue-Valleskey J; Yeo KP; Heathman M; Sinha V
J Pharmacokinet Pharmacodyn; 2013 Feb; 40(1):53-65. PubMed ID: 23263772
[TBL] [Abstract][Full Text] [Related]
10. AMG 151 (ARRY-403), a novel glucokinase activator, decreases fasting and postprandial glycaemia in patients with type 2 diabetes.
Katz L; Manamley N; Snyder WJ; Dodds M; Agafonova N; Sierra-Johnson J; Cruz M; Kaur P; Mudaliar S; Raskin P; Kewalramani R; Pellacani A
Diabetes Obes Metab; 2016 Feb; 18(2):191-5. PubMed ID: 26434934
[TBL] [Abstract][Full Text] [Related]
11. A comparison of preconstituted, fixed combinations of low-dose glyburide plus metformin versus high-dose glyburide alone in the treatment of type 2 diabetic patients.
Erle G; Lovise S; Stocchiero C; Lora L; Coppini A; Marchetti P; Merante D
Acta Diabetol; 1999 Jun; 36(1-2):61-5. PubMed ID: 10436254
[TBL] [Abstract][Full Text] [Related]
12. The glucokinase activator AZD6370 decreases fasting and postprandial glucose in type 2 diabetes mellitus patients with effects influenced by dosing regimen and food.
Ericsson H; Sjöberg F; Heijer M; Dorani H; Johansson P; Wollbratt M; Norjavaara E
Diabetes Res Clin Pract; 2012 Dec; 98(3):436-44. PubMed ID: 23010558
[TBL] [Abstract][Full Text] [Related]
13. Safety, pharmacokinetics and pharmacodynamics of multiple-ascending doses of the novel glucokinase activator AZD1656 in patients with type 2 diabetes mellitus.
Morrow LA; Leonsson-Zachrisson M; Ericsson H; Wollbratt M; Knutsson M; Hompesch M; Norjavaara E
Diabetes Obes Metab; 2012 Dec; 14(12):1114-22. PubMed ID: 22775976
[TBL] [Abstract][Full Text] [Related]
14. Tolerability, pharmacokinetics, and pharmacodynamics of the glucokinase activator AZD1656, after single ascending doses in healthy subjects during euglycemic clamp.
Ericsson H; Röshammar D; Wollbratt M; Heijer M; Persson M; Ueda S; Leonsson-Zachrisson M; Norjavaara E
Int J Clin Pharmacol Ther; 2012 Nov; 50(11):765-77. PubMed ID: 22943931
[TBL] [Abstract][Full Text] [Related]
15. Durability of efficacy and long-term safety profile of glyburide/metformin tablets in patients with type 2 diabetes mellitus: an open-label extension study.
Garber AJ; Bruce S; Fiedorek FT
Clin Ther; 2002 Sep; 24(9):1401-13. PubMed ID: 12380632
[TBL] [Abstract][Full Text] [Related]
16. Effect of exogenously administered glucagon versus spontaneous endogenous counter-regulation on glycaemic recovery from insulin-induced hypoglycaemia in patients with type 2 diabetes treated with a novel glucokinase activator, AZD1656, and metformin.
Krentz AJ; Morrow L; Petersson M; Norjavaara E; Hompesch M
Diabetes Obes Metab; 2014 Nov; 16(11):1096-101. PubMed ID: 24909093
[TBL] [Abstract][Full Text] [Related]
17. The combination metformin/glyburide exerts its hypoglycemic effect mainly by increasing insulin secretion: a controlled, randomized, double-blind, crossover study.
Gulias-Herrero A; Aguilar-Salinas CA; Gómez-Pérez FJ; Rull JA
Diabetes Nutr Metab; 2003; 16(5-6):268-76. PubMed ID: 15000437
[TBL] [Abstract][Full Text] [Related]
18. Dose-Dependent Effect of Piragliatin, a Glucokinase Activator, on the QT Interval Following Short-Term Multiple Doses in Patients With Type 2 Diabetes Mellitus.
Zhi J; Zhai S; Boldrin M
Clin Pharmacol Drug Dev; 2017 May; 6(3):258-265. PubMed ID: 27364955
[TBL] [Abstract][Full Text] [Related]
19. Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients.
Johnston PS; Lebovitz HE; Coniff RF; Simonson DC; Raskin P; Munera CL
J Clin Endocrinol Metab; 1998 May; 83(5):1515-22. PubMed ID: 9589648
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and pharmacodynamics of glyburide/metformin tablets (Glucovance) versus equivalent doses of glyburide and metformin in patients with type 2 diabetes.
Donahue SR; Turner KC; Patel S
Clin Pharmacokinet; 2002; 41(15):1301-9. PubMed ID: 12452739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
